垂体生长激素瘤继发糖尿病术前胰岛素泵控制血糖疗效分析  

Clinical Analysis of Insulin Pump in Treatment of Preoperation Pituitary GH Adenomas with Diabetes

作　　者：付景云[1] 史丽[1] 宋亚贤[1] 杨春爱[1] 

机构地区：[1]昆明医学院第一附属医院,云南昆明650000

出　　处：《中国医学创新》2012年第15期9-10,共2页Medical Innovation of China

基　　金：云南省教育厅基金资助项目(项目编号:2011Y182)

摘　　要：目的:比较垂体生长激素瘤继发糖尿病术前应用胰岛素泵(CSⅡ)与常规皮下注射胰岛素(MSⅡ)控制血糖疗效分析。方法:将164例垂体生长激素瘤继发糖尿病患者分为胰岛素泵组与常规皮下注射组,观察达标血糖控制的时间及每日所用的胰岛素剂量。结果:治疗后血糖降低两组(P<0.05)。两组治疗后空腹及餐后血糖下降水平,血糖波动幅度(mmol/L)及胰岛素用量,低血糖发生率(次数)比较,C组明显好于M组,两组比较差异有统计学意义(P<0.05)。结论:胰岛素泵连续皮下输注法能更稳定地控制垂体生长激素瘤继发糖尿病患者的血糖水平。Objective： To compare the effect of CS H and MS H therapy on preoperation pituitary GH adenomas with diabetes. Methods： The study included 164 pituitary GH adenomas with diabetes patients who were randomly divided into two groups and were given short-term CS Ⅱ and MS Ⅱ therapy, respectively. Blood glucose and the time of blood glucose up to target, total dose of insulin between two groups were compared. Results： The blood glucose decreased after treatment in the two groups（P〈0.05）. Compared with group MS Ⅱ, the time and total dose of insulin was lower in group CS Ⅱ with well glucose control. Conclusion： CS Ⅱ therapy can down regulate insulin resistance and well glucose control which is more evidently than MS Ⅱ therapy in preoperation pituitary GH adenomas with diabetes.

关 键 词：垂体生长激素瘤 糖尿病 胰岛素泵 

分 类 号：R736.4[医药卫生—肿瘤] R587.1[医药卫生—临床医学]